Machado PM, Barohn RJ, McDermott MP, Sundgreen C, Blaettler T, Hanna MG, et al. Design and rationale for a randomized, double-blind, placebo-controlled Phase 2/3 trial of oral arimoclomol in inclusion body myositis. rrnmf [Internet]. 2024 Sep. 4 [cited 2024 Nov. 21];5(2). Available from: https://journals.ku.edu/rrnmf/article/view/16244